Bad Tracleer data do Actelion good
This article was originally published in Scrip
Executive Summary
Actelion's share price rose 2.41% to CHF89.15 after it unveiled negative trial results for the drug that provides the lion's share of its revenues. The Swiss firm's long-marketed Tracleer (bosentan) for the serious orphan disease pulmonary arterial hypertension has failed a Phase IV study measuring its ability to prolong the time before patients progress to first morbidity or mortality when they are already being treated with another drug, sildenafil.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.